# Becton Dickinson (BDX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BDX
## Company Profile
- Ticker: BDX
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 181.41 USD
- Market cap: 39796303871.61 USD
- Last updated: 2026-08-11
## Business Overview
### Global Medical Technology
BD is a large medical-technology company supplying products used across medication delivery, connected care, biopharmaceutical manufacturing and interventional procedures.
### Medical Essentials
The company manufactures needles, syringes, catheters, vascular-access products and other high-volume devices used throughout hospitals and outpatient care.
### Connected Care and Biopharma Systems
BD provides infusion-management technology, medication-dispensing systems and drug-delivery components used by healthcare providers and pharmaceutical manufacturers.
### Interventional Portfolio
Its interventional business includes products for peripheral intervention, surgery, urology and critical care. Following the separation of its former Biosciences and Diagnostic Solutions businesses, BD has a more focused pure-play medtech profile.
## Why The Stock Is Moving

The latest monitored company update is “BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial.” The corresponding closing-price reaction is not yet available.

## Recent News
- 2026-08-12 10:50 EST — [BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial](https://biopharmsignal.com/news/BDX/bd-accelerates-advanced-tissue-regeneration-strategy-with-landmark-prevent-trial-db852f74) — Source: Becton Dickinson
- 2026-08-06 10:30 EST — [BD Reports Third Quarter Fiscal 2026 Financial Results](https://biopharmsignal.com/news/BDX/bd-reports-third-quarter-fiscal-2026-financial-results-eb2d4405) — Source: Becton Dickinson
- 2026-07-29 10:54 EST — [EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch](https://biopharmsignal.com/news/BDX/ems-and-bd-expand-access-to-glp-1-therapies-in-brazil-with-semaglutide-launch-ecbaad65) — Source: Becton Dickinson
- 2026-07-28 20:15 EST — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a) — Source: Becton Dickinson
- 2026-07-22 10:55 EST — [Mike Garrison to Retire from BD](https://biopharmsignal.com/news/BDX/mike-garrison-to-retire-from-bd-a251fa3e) — Source: Becton Dickinson